Delcath (DCTH) Reports 75% Accrual in Enrollment of Phase II Metastatic Melanoma Trial
Tweet Send to a Friend
Delcath Systems, Inc. (Nasdaq: DCTH) announced today that it has achieved the 75% enrollment point of its pivotal Phase III ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
